Product
US-Synagis®
1 clinical trial
1 indication
Indication
Healthy Control ParticipantsClinical trial
FANTASY-A Randomised, Double-Blind, 3-arm Parallel Study to Compare the Pharmacokinetics, Safety, Immunogenicity and Tolerability of MB05 (Proposed Palivizumab Biosimilar), EU-sourced Synagis® and US-sourced Synagis®, Administered as a Single Dose Intramuscular Injection in Healthy Volunteers.Status: Completed, Estimated PCD: 2023-03-31